Cat. No. 3393
Biological ActivityReversed amino acid sequence control peptide for TFLLR-NH2 (Cat. No. 1464), a PAR1 selective agonist that significantly increases nociceptive threshold.
(Modifications: Thr-5 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Buresi et al (2004) Activation of proteinase-activated receptor-1 inhibits neurally evoked chloride secretion in the mouse colon in vitro. Am.J.Physiol.Gastrointest.Liver Physiol. 288 G337. PMID: 15345469.
Fang et al (2003) Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin. J.Physiol. 549 903. PMID: 12717003.
Asfaha et al (2002) Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. Br.J.Pharmacol. 135 1101. PMID: 11877315.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for RLLFT-NH2 include:
Chen et al (2012) Thrombin activity associated with neuronal damage during acute focal ischemia. J Neurosci 32 7622. PMID: 22649241.
Do you know of a great paper that uses RLLFT-NH2 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: RLLFT-NH2, supplier, Control, peptide, TFLLR-NH2, PAR, Receptors, Protease-Activated, proteinase-activated, Tocris Bioscience, Protease-Activated Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonist
April 22 - 26, 2017
Chicago, IL, USA